The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Lancet Neurol. 2019 Sep;18(9):857-864. doi: 10.1016/S1474-4422(19)30196-6.
Uncertainty persists over the effects of blood pressure lowering in acute intracerebral haemorrhage. We aimed to combine individual patient-level data from the two largest randomised controlled trials of blood pressure lowering strategies in patients with acute intracerebral haemorrhage to determine the strength of associations between key measures of systolic blood pressure control and safety and efficacy outcomes.
We did a preplanned pooled analysis of individual patient-level data acquired from the main phase of the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2) and the second Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II) trial. These trials included adult patients aged 19-99 years with spontaneous (non-traumatic) intracerebral haemorrhage and elevated systolic blood pressure, without a clear indication or contraindication to treatment. Patients were excluded if they had a structural cerebral cause for the intracerebral haemorrhage, had a low score (3-5) on the Glasgow Coma Scale, or required immediate neurosurgery. Our primary analysis assessed the independent associations between three post-randomisation systolic blood pressure summary measures-magnitude of reduction in 1 h, mean achieved systolic blood pressure, and variability in systolic blood pressure between 1 h and 24 h-and the primary outcome of functional status, as defined by the distribution of scores on the modified Rankin Scale at 90 days post-randomisation. We analysed the systolic blood pressure measures as continuous variables using generalised linear mixed models, adjusted for baseline covariables and trial. The primary and safety analyses were done in a modified intention-to-treat population, which only included patients with sufficient data on systolic blood pressure.
3829 patients (mean age 63·1 years [SD 12·9], 1429 [37%] women, and 2490 [65%] Asian ethnicity) were randomly assigned in INTERACT2 and ATACH-II, with a median neurological impairment defined by scores on the National Institutes of Health Stroke Scale of 11 (IQR 6-16) and median time from the onset of symptoms of intracerebral haemorrhage to randomisation of 3·6 h (2·7-4·4). We excluded 20 patients with insufficient or no systolic blood pressure data, and we imputed missing systolic blood pressure data in 23 (1%) of the remaining 3809 patients. Overall, the mean magnitude of early systolic blood pressure reduction was 29 mm Hg (SD 22), and subsequent mean systolic blood pressure achieved was 147 mm Hg (15) and variability in systolic blood pressure was 14 mm Hg (8). Achieved systolic blood pressure was continuously associated with functional status (improvement per 10 mm Hg increase adjusted odds ratio [OR] 0·90 [95% CI 0·87-0·94], p<0·0001). Symptomatic hypotension occurred in 28 (1%) patients, renal serious adverse events occurred in 26 (1%) patients, and cardiac serious adverse events occurred in 99 (3%) patients.
Our pooled analyses indicate that achieving early and stable systolic blood pressure seems to be safe and associated with favourable outcomes in patients with acute intracerebral haemorrhage of predominantly mild-to-moderate severity.
None.
急性脑出血患者降压效果仍存在不确定性。我们旨在结合两项最大的急性脑出血降压策略随机对照试验的个体患者水平数据,以确定收缩压控制和安全性及疗效结局的关键指标之间的关联强度。
我们对来自急性脑出血强化降压试验(INTERACT2)和第二项抗高血压治疗急性脑出血(ATACH-II)试验的主要阶段获得的个体患者水平数据进行了一项预设的汇总分析。这些试验纳入了年龄在 19-99 岁之间、伴有自发性(非外伤性)脑出血和升高的收缩压、无明确降压治疗指征或禁忌证的成年患者。如果患者颅内出血有结构性脑原因、格拉斯哥昏迷量表评分(GCS)为 3-5 分,或需要立即神经外科治疗,则将患者排除在外。我们的主要分析评估了三个随机分组后收缩压汇总测量值(1 小时内收缩压降低幅度、平均达到的收缩压和 1 小时至 24 小时之间收缩压的变化)与主要结局(90 天随机分组后改良 Rankin 量表评分分布定义的功能状态)之间的独立关联。我们使用广义线性混合模型分析了收缩压测量值作为连续变量,根据基线协变量和试验进行了调整。主要和安全性分析在改良意向治疗人群中进行,该人群仅纳入了收缩压数据充足的患者。
3829 名患者(平均年龄 63.1 岁[SD 12.9],1429 名[37%]女性,2490 名[65%]为亚洲人种)被随机分配到 INTERACT2 和 ATACH-II 中,根据国立卫生研究院卒中量表(NIHSS)评分中位数定义的神经损伤程度为 11 分(IQR 6-16),从脑出血症状发作到随机分组的中位时间为 3.6 小时(2.7-4.4)。我们排除了 20 名收缩压数据不足或无收缩压数据的患者,并对剩余的 3809 名患者中的 23 名(1%)缺失的收缩压数据进行了推断。总体而言,早期收缩压降低幅度的平均值为 29mmHg(SD 22),随后达到的平均收缩压为 147mmHg(15),收缩压变化为 14mmHg(8)。达到的收缩压与功能状态持续相关(每增加 10mmHg,调整后的优势比[OR]为 0.90[95%CI 0.87-0.94],p<0.0001)。28 名(1%)患者发生症状性低血压,26 名(1%)患者发生严重肾脏不良事件,99 名(3%)患者发生严重心脏不良事件。
我们的汇总分析表明,在以轻度至中度为主的急性脑出血患者中,早期和稳定的收缩压似乎是安全的,并与良好的结局相关。
无。